KNO yields 1.06% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 9
Combined, KNO + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KNO + PFE for your $10,000?
KNO is actively managed to invest in a portfolio of large- and midcap companies perceived to be innovative potentially capturing outperformance through a knowledge effect. The fund will invest in developed market countries excluding Hong Kong, non-US stocks will have at least 40% exposure to these markets. KNOs proprietary model adjusts historical financial statements for intangibles and capitalizes a companys financial strength, profitability, and investment in innovation. After these adjustments, the fund adviser selects the most liquid companies. Intangible assets include R&D, advertising, brand development, and employee training expenses. Prior to May 26, 2020, the fund tracked the Knowledge Leaders Developed World Index. Also, Knowledge Leaders Capital, LLC replaced Exchange Traded Concepts, LLC as its investment adviser. On July 22, 2023, the ETF acquired all assets and liabilities of the Knowledge Leaders Developed World ETF (KLDW), which had about $130 million in assets.
Full KNO Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.